癌症中聚（ADP - 核糖）聚合酶的抑制作用

Inhibition of poly(ADP-ribose) polymerase in cancer.

作者信息

Plummer Elizabeth Ruth

机构信息

Northern Institute for Cancer Research, Paul O'Gorman Building, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.

出版信息

Curr Opin Pharmacol. 2006 Aug;6(4):364-8. doi: 10.1016/j.coph.2006.02.004. Epub 2006 Jun 5.

DOI:10.1016/j.coph.2006.02.004

PMID:16753340

Abstract

Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.

摘要

在临床前研究中，作为一种化疗或放疗增敏策略，DNA修复酶聚（ADP - 核糖）聚合酶-1（PARP-1）的抑制作用已得到广泛研究。最近有证据表明，PARP抑制剂在某些携带DNA修复缺陷的罕见遗传性癌症中可能作为单一药物发挥作用。因此，强效PARP-1抑制剂在过去三年已进入癌症患者的早期临床试验，人们急切期待这些试验的最终结果。